|Bid||67.00 x 0|
|Ask||72.00 x 0|
|Day's Range||68.00 - 72.00|
|52 Week Range||0.78 - 94.50|
|Beta (5Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||200.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NSCI.LLearn more
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Wanda Health Inc CEO Tom Smith visits the Proactive London studio to speak with Thomas Warner about the company's journey toward becoming "truly an AI-driven healthcare organisation."
Nanalysis Scientific Corp. (TSXV:NSCI, OTCQX:NSCIF, FRA:1N1) ("Nanalysis" or the "Company") announces that Company CEO Sean Krakiwsky has been invited to present on the panel "Growing Opportunities in Industrial & Medical Markets" at the Industrial Tech Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, March 21st 2023 at 1:00 p.m. ET.
Nanalysis Scientific Corp. (TSXV:NSCI, OTCQX:NSCIF, FRA:1N1) ("Nanalysis" or the "Company") announces that the Company's Board of Directors has granted 335,000 stock options to Directors and Officers of the Company, pursuant to the Company's stock option plan. Each option is exercisable to purchase one common share in the capital of the Company at $1.10 per share for a period of five years from the date of issuance. The options vest as to one-third on each of the 12 month, 24 month, and 36 month